StockIQpro
NASDAQ:AURA

Aura Biosciences, Inc.

Track all markets on TradingView
Track all markets on TradingView

Aura Biosciences, Inc. reported net income of −$106.2M in fiscal 2025. Free cash flow was −$85.2M, and the diluted share count rose 21.5%.Summary generated from Aura Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−73.5%
Debt / equityn/a
Free cash flow−$85.2M
FCF marginn/a
Share count change+21.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−35−60−85−96−113
Net income−35−59−76−87−106
Free cash flow−35−56−65−81−85

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)